RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

From a scientific standpoint this looks pretty clean. I don't think that the big boys are holding back, I think they're not paying attention yet. A partnership will bring the attention. That partnership is coming, since these compounds offer a substantial advantage to any BP interested in developing analgesics for severe chronic pain. If the RD-1 study shows a trend in the E50 data, and robust preservation of analgesia, we're good to go.

I'd be surprised (based on the animal data) if analgesia were lost.